Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma
Chen Shen, Mei Li, Yujuan Duan, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12

Showing 12 citing articles:

HDAC inhibitors and IBD: Charting new approaches in disease management
Xueting Du, Weilai Yu, Fangyu Chen, et al.
International Immunopharmacology (2025) Vol. 148, pp. 114193-114193
Closed Access
Noval advance of histone modification in inflammatory skin diseases and related treatment methods
Lichen Zhang, Rongrong Chai, Zongguang Tai, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 6
Cellular Epigenetic Targets and Epidrugs in Breast Cancer Therapy: Mechanisms, Challenges, and Future Perspectives
Ibrahim S. Alalhareth, Saleh M. Alyami, Abdulrhman Alshareef, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 207-207
Open Access
Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
Rui Han, Changquan Ling, Yuqian Wang, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance
Liqin Yao, Qingqing Wang, Wenxue Ma
Cancers (2023) Vol. 15, Iss. 24, pp. 5857-5857
Open Access | Times Cited: 12
An oncogene regulating chromatin favors response to immunotherapy
Leqian Ying, Zhangmin Hu, Yi Lü, et al.
OncoImmunology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 3
Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review
Asghar Arshi, Esmaeil Mahmoudi, Farzaneh Raeisi, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Chromatin Remodeling-Related PRDM1 Increases Stomach Cancer Proliferation and Is Counteracted by Bromodomain Inhibitor
Yu‐Hsuan Hung, Hui‐Ching Wang, Mei‐Ren Pan, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 3, pp. 224-224
Open Access
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy
Bocheng Wu, Subhasish Tapadar, Zhiping Ruan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy
Bocheng Wu, Subhasish Tapadar, Zhiping Ruan, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 10, pp. 3155-3169
Open Access
Epigenetic Alterations in Oral Cancer: Mechanisms, Biomarkers, and Therapeutic Targets
Madhan Krishnan, Basappa Basappa, Shyamaladevi Babu
Oral Oncology Reports (2024) Vol. 12, pp. 100681-100681
Open Access
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms
Tyce Kearl, Fateeha Furqan, Nirav N. Shah
Cancer and Metastasis Reviews (2024) Vol. 44, Iss. 1
Closed Access
Page 1

Scroll to top